Stock Analiz

BIO-TECHNE Corp (TECH) financials: revenue, earnings and cash flow

Fiscal 2017–2026 + TTM · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2026 was $182M, a net margin of 15.0%; the best year in this period was 2023 with $285M.

Over the twelve months to September 30, 2026, revenue was $1.2B and net income $172M.

Free cash flow was $263M in fiscal 2026 and positive in 9 of the 10 years shown.

Revenue, profit and cash flow by year

Revenue
2018: $643M182019: $714M192020: $739M202021: $931M212022: $1.1B222023: $1.1B232024: $1.2B242025: $1.2B252026: $1.2B26$1.2B
Net income
2017: $49M172018: $126M182019: $96M192020: $229M202021: $140M212022: $272M222023: $285M232024: $168M242025: $73M252026: $182M26$182M
Free cash flow
2018: $149M182019: $156M192020: $153M202021: $308M212022: $280M222023: $216M232024: $236M242025: $257M252026: $263M26$263M
EPS (diluted)
2018: $0.83182019: $0.62192020: $1.46202021: $0.87212022: $1.66222023: $1.76232024: $1.05242025: $0.46252026: $1.1626$1.16

Income statement

Fiscal yearTTM2026202520242023202220212020201920182017
Revenue$1.2B$1.2B$1.2B$1.2B$1.1B$1.1B$931M$739M$714M$643M—
Gross profit$808M$799M$790M$770M$770M$756M$633M$483M$473M$432M—
Operating income$241M$252M$102M$207M$299M$297M$237M$157M$147M$136M—
Net income$172M$182M$73M$168M$285M$272M$140M$229M$96M$126M$49M
EPS (diluted)$1.09$1.16$0.46$1.05$1.76$1.66$0.87$1.46$0.62$0.83—
R&D$97M$95M$99M$97M$92M$87M$71M$65M$62M$55M—
Revenue growth—−0.4%+5.2%+2.0%+2.8%+18.8%+26.0%+3.5%+11.0%——

Cash flow

Fiscal yearTTM2026202520242023202220212020201920182017
Operating cash flow$338M$292M$288M$299M$254M$325M$352M$205M$182M$170M—
Capital spending-$29M-$29M-$31M-$63M-$38M-$45M-$44M-$52M-$25M-$21M—
Free cash flow$308M$263M$257M$236M$216M$280M$308M$153M$156M$149M—
Dividends paid$50M$50M$50M$50M$50M$50M$50M$49M$48M$48M—
Buybacks—$42M$276M$80M$20M$161M$43M$50M$15M$0—
Stock-based pay$43M$41M$41M$38M$39M$42M$49M$32M$32M$28M—

Balance sheet

Fiscal yearTTM2026202520242023202220212020201920182017
Cash—$265M$162M$153M$204M$247M$232M$147M$101M$122M—
Debt—$289M$790M$739M$455M$326M$421M$434M$505M$339M—
Equity—$2.1B$1.9B$2.1B$2.0B$1.7B$1.6B$1.4B$1.2B$1.1B—
Total assets—$2.6B$2.6B$2.7B$2.6B$2.3B$2.3B$2.0B$1.9B$1.6B—
Shares (diluted)158M157M160M161M162M164M162M158M156M152M—

Margins and returns

Fiscal yearTTM2026202520242023202220212020201920182017
Gross margin65.8%65.8%64.8%66.4%67.7%68.4%68.0%65.4%66.3%67.2%—
Operating margin19.6%20.7%8.4%17.8%26.3%26.8%25.5%21.3%20.5%21.2%—
Net margin14.0%15.0%6.0%14.5%25.1%24.6%15.1%31.0%13.5%19.6%—
FCF margin25.1%21.7%21.0%20.4%19.0%25.4%33.1%20.8%21.9%23.2%—
ROIC—7.9%2.8%6.7%10.4%12.8%11.3%7.2%7.5%7.6%—
ROE—8.6%3.8%8.1%14.5%16.0%9.0%16.6%8.2%11.7%—

Frequently asked questions

What is BIO-TECHNE’s annual revenue?

$1.2B in fiscal 2026 and $1.2B over the twelve months to September 30, 2026.

How much profit does BIO-TECHNE make?

Net income was $182M in fiscal 2026 (net margin 15.0%).

Is BIO-TECHNE’s revenue growing?

No: revenue fell 0.4% in fiscal 2026 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.